Zydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFDA is expected to complete its review process by the third quarter of 2027. This biosimilar, named FYB206, was developed without a comparative Phase III efficacy trial. Zydus aims to make effective treatments more accessible in the oncology field in North America.
RSS News
Economic times
0 thoughts on “Zydus moves closer to US market for Keytruda biosimilar as FDA accepts application”
Leave a Reply
Your email address will not be published. Required fields are marked *
RECENT NEWS
- Madhoo backs Rashmika Mandanna over South Indian accent criticism; says ‘own it, girl’
- Ayushmann Khurrana about an early rejection story involving Karan Johar
- Saiee M Manjrekar’s look from Ram Charan-backed ‘The India House’ leaks
- Kamal reveals how Mammootty’s joke led to ‘Mazhayethum Munpe’
- Student sets mehndi record in Karnataka
